WO2008059372A3 - Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt - Google Patents

Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt Download PDF

Info

Publication number
WO2008059372A3
WO2008059372A3 PCT/IB2007/003636 IB2007003636W WO2008059372A3 WO 2008059372 A3 WO2008059372 A3 WO 2008059372A3 IB 2007003636 W IB2007003636 W IB 2007003636W WO 2008059372 A3 WO2008059372 A3 WO 2008059372A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzylcarbamoyl
pyrazol
fluoro
isopropyl
phenyl
Prior art date
Application number
PCT/IB2007/003636
Other languages
French (fr)
Other versions
WO2008059372A2 (en
Inventor
Jonathan M Miller
Original Assignee
Pfizer Prod Inc
Jonathan M Miller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Jonathan M Miller filed Critical Pfizer Prod Inc
Publication of WO2008059372A2 publication Critical patent/WO2008059372A2/en
Publication of WO2008059372A3 publication Critical patent/WO2008059372A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A crystal form A of sodium; (3R, 5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl- benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dιhydroxy-heptanoic acid is provided.
PCT/IB2007/003636 2006-11-17 2007-11-16 Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt WO2008059372A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86632906P 2006-11-17 2006-11-17
US60/866,329 2006-11-17

Publications (2)

Publication Number Publication Date
WO2008059372A2 WO2008059372A2 (en) 2008-05-22
WO2008059372A3 true WO2008059372A3 (en) 2009-01-29

Family

ID=39402058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003636 WO2008059372A2 (en) 2006-11-17 2007-11-16 Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt

Country Status (1)

Country Link
WO (1) WO2008059372A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia

Also Published As

Publication number Publication date
WO2008059372A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
NZ591818A (en) Processes for the preparation of sglt2 inhibitors
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2006072393A3 (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
PE20130239A1 (en) HETEROARYL-ARYL-UREAS COMPOUNDS AS KINASE INHIBITORS
WO2007035629A3 (en) Process for the preparation of pyrimidinedione derivatives
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
EP2182950B8 (en) Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
WO2006071762A3 (en) Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
SG166829A1 (en) Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2008079787A8 (en) Glucokinase activators
WO2009114181A3 (en) Substituted heterocycle fused gamma-carbolines solid
WO2006052568A3 (en) Tgf-beta inhibitors
WO2009145456A3 (en) Heterocyclic derivatives
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
WO2007117995A3 (en) Kinase inhibitors
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2009068463A3 (en) Process for the preparation of isoindole derivatives as well as a process for the preparation of their intermediates
WO2007062314A3 (en) Heterocyclic cetp inhibitors
WO2006066044A3 (en) Processes for producing 4-aminoquinazolines
WO2008079266A3 (en) Synthesis of pyrrolidine compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 198235

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07825736

Country of ref document: EP

Kind code of ref document: A2